Article (Scientific journals)
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study
Baron, Frédéric; Efficace, F.; Cannella, L. et al.
2020In American Journal of Hematology, 95 (7), p. 749-758
Peer Reviewed verified by ORBi
 

Files


Full Text
baron2020.pdf
Publisher postprint (3.17 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Article; HLA matching
Abstract :
[en] We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m2), mitoxantrone (MXR, 12 mg/m2), or idarubicin (IDA, 10 mg/m2) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P =.38). In young patients, 15-45 years old, no treatment difference (P =.89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P =.029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients. © 2020 Wiley Periodicals, Inc.
Disciplines :
Hematology
Author, co-author :
Baron, Frédéric  ;  Université de Liège - ULiège > I3-Hematology
Efficace, F.;  Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Cannella, L.;  Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Muus, P.;  Radboud University Medical Center, Nijmegen, Netherlands
Trisolini, S.;  Sapienza University, Rome, Italy
Halkes, C. J. M.;  Leiden University Medical Center, Leiden, Netherlands
Fazi, P.;  Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Vignetti, M.;  Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Marie, J.-P.;  Saint-Antoine Hospital, Paris, France
Chiusolo, P.;  Gemelli Hospital, Rome, Italy
van der Velden, W.;  Radboud University Medical Center, Nijmegen, Netherlands
La Sala, E.;  Gruppo Italiano Malattie Ematologiche Dell'Adulto GIMEMA, Rome, Italy
Vitolo, U.;  Candiolo Cancer Institute-IRCCS, Torino, Italy
Thomas, X.;  Lyon-Sud University Hospital, Lyon, France
Lefrère, F.;  Assistance Publique-Hôpitaux de Paris, Necker Children's Hospital, Paris, France
Di Raimondo, F.;  Universita di Catania, Catania, Italy
Bourhis, J.-H.;  Gustave Roussy cancer campus Grand Paris, Villejuif, France
Specchia, G.;  Giovanni XXIII- University Hospital, Bari, Italy
Guimarães, J. E.;  Hospital S. João, Porto, Portugal
Allione, B.;  Candiolo Cancer Institute-IRCCS, Torino, Italy
Vrhovac, R.;  University Hospital Centre Zagreb, Zagreb, Croatia
Ferrara, F.;  Cardarelli Hospital, Naples, Italy
Stevens-Kroef, M.;  Radboud University Medical Center, Nijmegen, Netherlands
Meert, L.;  EORTC Headquarters, Brussels, Belgium
de Witte, T.;  Radboud University Medical Center, Nijmegen, Netherlands
Willemze, R.;  Leiden University Medical Center, Leiden, Netherlands
Amadori, S.;  University Tor Vergata, Rome, Italy
Suciu, S.;  EORTC Headquarters, Brussels, Belgium
More authors (18 more) Less
Language :
English
Title :
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study
Publication date :
2020
Journal title :
American Journal of Hematology
ISSN :
0361-8609
eISSN :
1096-8652
Publisher :
Wiley-Liss Inc.
Volume :
95
Issue :
7
Pages :
749-758
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Fondation contre le CancerNovartisH. Lundbeck A/SAbbVieTeva Pharmaceutical IndustriesSanofiCelgeneAmgen
Available on ORBi :
since 03 September 2020

Statistics


Number of views
214 (2 by ULiège)
Number of downloads
273 (2 by ULiège)

Scopus citations®
 
13
Scopus citations®
without self-citations
4
OpenCitations
 
12

Bibliography


Similar publications



Contact ORBi